Vaccines

Transforming clinical development of vaccines

Development of new vaccines presents an array of challenges, including recruiting special populations,  addressing fragile viral sample logistics and entering endemic geographies—often under tight timelines.


To help address these challenges, Quintiles’ dedicated team of vaccine experts enabled by a global network of high-enrolling hubs and technology platforms deliver rapid and predictable timelines and more cost-effective trials while optimizing the quality of clinical and commercial outcomes.

banner_man with beaker

Quintiles helped develop or commercialize 100% (35 of 35) of 2013’s top selling vaccine products

Reach the right sites and subjects quickly and efficiently with global network of high-enrolling vaccine hubs

With experience in more than 110 vaccine studies involving over 250,000 subjects, and up to 4X more efficient vaccine enrollment rates (patients/site/month) compared to CMR industry benchmarks, you can be confident enrollment will be accelerated and start up timelines are met.   
Our global vaccine hubs—high enrolling sites in the right locations to accommodate northern and southern hemisphere studies and  endemic geographies—for a variety of viruses including  influenza, pneumococcal, norovirus, malaria, TB, dengue, HIV, and other indications.  

Ensure data quality and integration for improved outcomes

Benefit from seamless data integration across all phases of development with Quintiles’ Infosario ®platform.  Near real time access to data and study views is also enabled as is risk based monitoring accommodating a mix of on-site and remote site visits. 

For data capture, choose traditional electronic data capture (EDC) or eSource technology.  In the latter, source data is captured directly into the study database.  The need for manual data transcription and transcription source data verification (SDV) is eliminated, improving timelines, quality, and efficiency.    

Reach your trial goals sooner and more predictably

Timelines are a critical piece to all clinical trials. With our unique combination of integrated start up, global vaccine hubs, and full service trial execution with technology platforms, you can save an estimated 16+ weeks  in the overall vaccine trial timeline.  

Quintiles Vaccine offering provides rapid and efficient cycle times.  When compared to CMR industry benchmarks* we can help you achieve up to:
  • 15% faster start up
  • 18% faster enrollment  
  • 72% faster database lock 
  • 43% faster total study duration

*Compared to industry benchmarks defined by CMB International, a Thompson-Reuters company. Cycle time refects median number of days for Phase II / III / IIIb studies combined for 2008-2012

Vaccine lab testing aligns to global vaccine hubs for optimal data quality

Leverage the world’s largest CAP accredited global central network, with sites in all major regions in proximity of our global vaccine hubs including a specialty tuberculosis lab in South Africa.  Scientific experts work in state of the art facilities and on platforms including molecular, flow cytometry, single plex and multiplex immunoassays to ensure your serology, virology, and other assay needs are met.  

Integrate across clinical, regulatory, commercial expertise for improved outcomes

The Vaccines Center of Excellence (COE) at Quintiles provides global expertise in vaccines and pediatrics, helping sponsors integrate operational, regulatory and commercial aspects of their programs for improved outcomes.  

The COE can help plan and implement ancillary services including planning and design, biostatistics, medical writing, pharmacovigilance, data-safety management boards, and real world-late phase studies, all available on an as-needed basis. 
  • 99% Global average GCP and Protocol compliance for Vaccine studies since 20081

The power of possibilities

Transform your vaccine program and improve probability for success:
Partner with Quintiles and align with global sites and resources, integrated technologies, and vaccine expertise.

Related Services

Central Laboratories
Infectious Disease
Public Health

Quintiles Expert

Senior Vice President and Global Head, Early Clinical Development

Recent thinking: Why We Need to Lead with Science

Vice President, Allergy, Respiratory, Infectious Diseases and Vaccines

Recent thinking: Tropical Diseases Go Global